Prehypertension and Cardiometabolic Syndrome

This book sheds new light on the management of patients with borderline cardiovascular risk factors in order to prevent their progression to end organ damage. The book stimulates discussion of this poorly understood condition and lays the groundwork for developing recommendations and guidelines. Whi...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Άλλοι συγγραφείς: Zimlichman, Reuven (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt), Julius, Stevo (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt), Mancia, Giuseppe (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Cham : Springer International Publishing : Imprint: Springer, 2019.
Έκδοση:1st ed. 2019.
Σειρά:Updates in Hypertension and Cardiovascular Protection,
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 06980nam a2200565 4500
001 978-3-319-75310-2
003 DE-He213
005 20191027151023.0
007 cr nn 008mamaa
008 181206s2019 gw | s |||| 0|eng d
020 |a 9783319753102  |9 978-3-319-75310-2 
024 7 |a 10.1007/978-3-319-75310-2  |2 doi 
040 |d GrThAP 
050 4 |a RC681-688.2 
072 7 |a MJD  |2 bicssc 
072 7 |a MED010000  |2 bisacsh 
072 7 |a MJD  |2 thema 
082 0 4 |a 616.12  |2 23 
245 1 0 |a Prehypertension and Cardiometabolic Syndrome  |h [electronic resource] /  |c edited by Reuven Zimlichman, Stevo Julius, Giuseppe Mancia. 
250 |a 1st ed. 2019. 
264 1 |a Cham :  |b Springer International Publishing :  |b Imprint: Springer,  |c 2019. 
300 |a XII, 689 p. 111 illus., 72 illus. in color.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a Updates in Hypertension and Cardiovascular Protection,  |x 2366-4606 
505 0 |a I Epidemiology and Statistics -- 1 Epidemiology, statistics and health burden -- 2 PreHypertension, the risk of Hypertension and events -- 3 Parental history of hypertension as the determinant of cardiovascular function -- 4 High normal blood pressure in children and adolescents -- II Pathophysiology of prehypertension.­- Part 1 Alteration of Cardiovascular control systems -- 5 Tachycardia in PreHypertension -- 6 Endothelial dysfunction in early phases of hypertension -- 7 Prehypertension and the Renin angiotensin aldosterone system -- 8 The role of the brain in neurogenic prehypertension -- 9 The blood pressure seeking property of the brain -- Part 2 Organ damage in Prehypertension -- 10 Microvascular structural alternations and tissue perfusion in hypertension and diabetes.-11 The heart in prehypertension -- 12 The role of the kidney in PreHypertension -- 13 Obesity, Hypertension and Chronic Kidney Disease: A Forty Year Retrospective -- 14 Pre-CKD? Early markers of renal dysfunction in patients with Prehypertension -- 15 Arterial stiffness in early phases of Prehypertension -- 16 The role of perivascular fat in raising blood pressure in obesity and diabetes -- 17 The Brain -- 18 Diurnal and pulsatile hemodynamics in individuals with PreHypertension -- 19 Systolic hypertension in youth -- 20 Prehypertension and ethnicity: Haemodynamic mechanisms in young adults -- 21 Hemodynamics (systemic and renal) in prehypertension -- 22 Central blood pressure and Prehypertension -- Section 3: Risk assessment in PreHypertension -- 23 Blood pressure measurement, white coat and masked hypertension.-24 Vascular functional and structural risk assessment in prehypertension -- 25 Blood pressure variability -- 26 Morning Surge of Blood Pressure -- 27 Role of ambulatory Blood Pressure Monitoring in Prehypertension -- 28 Home blood pressure, prehypertension and hypertension -- 29 Blood pressure and atherosclerosis- subclinical arteriosclerosis as an early sign of organ damage -- 30 Response to stress, effort and cold pressor test as predictors of Prehypertension -- 31 Physical Activity and Exercise Training as Important Modifiers of Vascular Health -- 32 Prehypertension and associated metabolic risk factors -- IV End organ damage in PreHypertension -- 33 Early cardiovascular dysfunction in Prehypertension -- 34 Effect of blood pressure lowering in hypertensive rats -- V Clinical studies in PreHypertension -- 35 Review of "old and new studies" in the treatment of PreHypertension -- 36 The CHINON study- argument for early treatment of PreHypertension. Effect of age on progression of hypertension -- 37 The PREVER study -- 38 The TROPHY study -- VI Management of PreHypertension -- 39 Non-pharmacologic approaches for the management of prehypertension -- 40 Antihypertensive drugs and vascular health -- 41 Prehypertension: a case in favor of early use of diuretics -- 42 Treatment of High normal blood pressure in the guidelines -- VII Tentative additional chapters -- 43 History of prehypertension: a saga of misunderstanding and neglect -- 44 Management of Prehypertension and hypertension in women of reproductive age. 
520 |a This book sheds new light on the management of patients with borderline cardiovascular risk factors in order to prevent their progression to end organ damage. The book stimulates discussion of this poorly understood condition and lays the groundwork for developing recommendations and guidelines. While the diagnostic and therapeutic approach to full-blown diabetes, hypertension, dyslipidemia and obesity is well defined, there is still a lack of clear understanding and guidelines as far as patients with borderline conditions - especially when multiple - are concerned. Moreover, end-organ damage depends on several factors, including genetic factors, making it difficult to predict its extent. As such, the gradual transition from a healthy subject to one with functional hemodynamic changes, and then one with structurally asymptomatic changes and lastly to overt disease needs further investigation. In order to address these knowledge gaps, the book covers a broad variety of topics, making it a valuable tool for identifying which asymptomatic subjects could profit from being appropriately screened and at what stage. Furthermore it offers insights into better treating these patients to prevent their progression to overt disease. The book appeals to cardiologists, primary care physicians and all those healthcare professional looking to optimize the management of these complex and often undiagnosed cases. 
650 0 |a Cardiology. 
650 0 |a Angiology. 
650 0 |a Diabetes. 
650 0 |a Metabolic diseases. 
650 0 |a Primary care (Medicine). 
650 1 4 |a Cardiology.  |0 http://scigraph.springernature.com/things/product-market-codes/H33037 
650 2 4 |a Angiology.  |0 http://scigraph.springernature.com/things/product-market-codes/H33010 
650 2 4 |a Diabetes.  |0 http://scigraph.springernature.com/things/product-market-codes/H33045 
650 2 4 |a Metabolic Diseases.  |0 http://scigraph.springernature.com/things/product-market-codes/H33118 
650 2 4 |a Primary Care Medicine.  |0 http://scigraph.springernature.com/things/product-market-codes/H51000 
700 1 |a Zimlichman, Reuven.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
700 1 |a Julius, Stevo.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
700 1 |a Mancia, Giuseppe.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
776 0 8 |i Printed edition:  |z 9783319753096 
776 0 8 |i Printed edition:  |z 9783319753119 
830 0 |a Updates in Hypertension and Cardiovascular Protection,  |x 2366-4606 
856 4 0 |u https://doi.org/10.1007/978-3-319-75310-2  |z Full Text via HEAL-Link 
912 |a ZDB-2-SME 
950 |a Medicine (Springer-11650)